AOTMiT: Transparency Council to evaluate drugs for drug-resistant epilepsy and melanoma, among others

The agenda includes:

1 Prepare a position paper on qualifying health care services: Branched-chain amino acids in "dry" blood drop; Amino acid profile in plasma/serum or urine; Amino acid and acylcarnitine profile in "dry" blood drop; Organic acid profile in urine GC/MS; Succinylacetone in "dry" blood drop; Total homocysteine, methylmalonic acid and methylcitric acid in "dry" blood drop; Pterins in urine" as guaranteed benefits.

2 Prepare a position paper on the legitimacy of issuing approvals for reimbursement of medicinal products Petinimid, Petnidan/Petnidan Saft (ethosuximidum) in the indication: drug-resistant epilepsy (including epilepsy with absence seizures), continuous discharge syndrome in slow-wave sleep.

3 Prepare an opinion on the inclusion in reimbursement of medicinal products containing the active substance pembrolizumabum within the framework of the drug program B.59 "Treatment of patients with melanoma of the skin or mucous membranes (ICD-10: C43)".

4 Prepare an opinion on the inclusion in reimbursement of medicinal products containing the active substance abirateronum in the indication: treatment of adult patients under complementary hormone therapy in combination with androgen suppression therapy, from a high-risk group after radical radiotherapy.

5. Prepare an opinion on the continuation of the inclusion in reimbursement of medicinal products containing the active substances levodopum + benserazidum, levodopum + carbidopum in the indication: levodopa-sensitive dystonia other than in the course of Parkinson's disease and syndrome; tyrosine hydroxylase deficiency.

6 Prepare an opinion on the continuation of coverage of medicinal products containing the active substances lamotrigine, valproic acid, venlafaxine in the indication: neuralgia or neuropathy in the face.

7 Prepare an opinion on the continuation of coverage of medicinal products containing the active substance doxorubicinum liposomanum in the indication: cancer in patients with significant risk factors for serious cardiovascular events, taking into account contraindications:

1) symptomatic heart failure (NYHA class III or IV); 2) left ventricular systolic dysfunction EF< 6 weeks; 4) history of documented ventricular tachycardia; 5) poorly controlled hypertension; 6) unstable angina (CCS class III or IV); [unwarranted contraindications: 1) coronary artery disease; 2) insulin-dependent diabetes mellitus; 3) persistent atrial fibrillation; 4) ventricular arrhythmia; 5) moderate aortic valve stenosis; 6) hypertension with complications] qualified by the following ICD10 diagnoses: C81 Hodgkin's disease; C81.0 lymphocyte predominance; C81.1 nodular sclerosis; C81.2 mixed cell; C81.3 lymphocyte reduction; C81.7 other Hodgkin's disease; C81.9 Hodgkin's disease, unspecified; C82 Nodular (nodular) non-Hodgkin's lymphoma; C82.0 of small indented (slit = cleaved) cells, nodular; C82.1 mixed of small indented (slit = cleaved) and large cells, nodular; C82.2 large cell, nodular; C82.7 other forms of nodular non-Hodgkin's lymphoma; C82.9 non-Hodgkin's lymphoma, unspecified; C83 diffuse non-Hodgkin's lymphomas; C83.0 of small cells (diffuse); C83.1 of small indented (slit = cleaved) cells (diffuse); C83.2 mixed of large and small cells (diffuse); C83.3 large cell (diffuse); C83.4 immunoblastic (diffuse); C83.5 lymphoblastic (diffuse); C83.6 undifferentiated (diffuse); C83.7 Burkitt's tumor (lymphoma); C83.8 other forms of diffuse non-Hodgkin's lymphoma; C83.9 diffuse non-Hodgkin's lymphoma, unspecified; C84 peripheral and cutaneous T-cell lymphoma; C84.0 mycosis fungoides granulomatosis; C84.1 Sezary's disease; C84.2 T-zone lymphoma; C84.3 lymphoepithelioid lymphoma; C84.4 peripheral T-cell lymphoma; C84.5 other and unspecified T-cell lymphoma; C85 other and unspecified forms of non-Hodgkin's lymphoma; C85.0 lymphosarcoma; C85.1 B-cell lymphoma, unspecified; C85.7 other specified forms of non-Hodgkin's lymphoma; C85.9 non-Hodgkin's lymphoma, unspecified.

8 Prepare an opinion on the draft health policy program "Pneumococcal infection prevention program for residents of Gdynia aged 55 and over for 2024 - 2025".

9. Prepare an opinion on the draft health policy program "Program of screening for thyroid diseases in women in the procreative period from 18 to 35 years of age".

10. Prepare an opinion on the draft health policy program "Health policy program "Health policy program on postnatal care for residents of the Mazovian province".

Source: AOTMiT